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Expected Value of Sample Information to
Guide the Design of Group Sequential
Clinical Trials
Laura Flight , Steven Julious, Alan Brennan, and Susan Todd
Introduction. Adaptive designs allow changes to an ongoing trial based on prespecified early examinations of accrued
data. Opportunities are potentially being missed to incorporate health economic considerations into the design of
these studies. Methods. We describe how to estimate the expected value of sample information for group sequential
design adaptive trials. We operationalize this approach in a hypothetical case study using data from a pilot trial. We
report the expected value of sample information and expected net benefit of sampling results for 5 design options for
the future full-scale trial including the fixed-sample-size design and the group sequential design using either the
Pocock stopping rule or the O’Brien-Fleming stopping rule with 2 or 5 analyses. We considered 2 scenarios relating
to 1) using the cost-effectiveness model with a traditional approach to the health economic analysis and 2) adjusting
the cost-effectiveness analysis to incorporate the bias-adjusted maximum likelihood estimates of trial outcomes to
account for the bias that can be generated in adaptive trials. Results. The case study demonstrated that the methods
developed could be successfully applied in practice. The results showed that the O’Brien-Fleming stopping rule with
2 analyses was the most efficient design with the highest expected net benefit of sampling in the case study. Conclu-
sions. Cost-effectiveness considerations are unavoidable in budget-constrained, publicly funded health care systems,
and adaptive designs can provide an alternative to costly fixed-sample-size designs. We recommend that when plan-
ning a clinical trial, expected value of sample information methods be used to compare possible adaptive and nona-
daptive trial designs, with appropriate adjustment, to help justify the choice of design characteristics and ensure the
cost-effective use of research funding.
Highlights
 Opportunities are potentially being missed to incorporate health economic considerations into the design of
adaptive clinical trials.
 Existing expected value of sample information analysis methods can be extended to compare possible group
sequential and nonadaptive trial designs when planning a clinical trial.
 We recommend that adjusted analyses be presented to control for the potential impact of the adaptive
designs and to maintain the accuracy of the calculations.
 This approach can help to justify the choice of design characteristics and ensure the cost-effective use of
limited research funding.
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Conducting efficient research is a priority for funders
with limited heath research budgets.1 Adaptive designs
are one way to potentially make a trial more efficient
that use data collected as a trial progresses, at
prespecified time points, to inform modifications to the
trial.2 They can directly benefit patients and health care
providers both ethically and financially.3,4 Adaptive
designs are increasingly used5–7 and have been adopted
in trials for the treatment of COVID-19.8
The methods of value-of-information analysis (VOIA)
provide a framework for quantifying the value of collect-
ing more information to determine whether a treatment
should be adopted by balancing the benefits of additional
research against the costs. To date, opportunities are
potentially being missed to apply VOIA methods into
the design and analysis of adaptive designs.9,10
In this article, we extend existing VOIA methods, spe-
cifically the expected value of sample information (EVSI)
for assessing the cost-effectiveness of proposed fixed-
sample-size designs to the adaptive design setting.11 This
approach helps to increase the efficiency of trials while
reflecting stakeholder preferences for adaptive decisions
to be informed by clinical effectiveness during the trial.11
We highlight how this approach differs from the fixed-
sample-size design setting using the ISPOR Value of
Information Emerging Good Practices Task Force
framework.10,12 Key considerations include appropri-
ately adjusting estimates for the adaptive nature of the
design as well as capturing the costs associated with con-
ducting an adaptive design.
Using a hypothetical case study, based on the CAC-
TUS pilot trial,13 the methods are used to guide the
design of a trial focusing on the number of interim analy-
ses and choice of clinical effectiveness stopping rule while
making appropriate adjustments for the adaptive nature
of the design.
Group Sequential Designs
Pallmann et al.4 provided a summary of available adap-
tive designs. In this article, we focus on the commonly
used group sequential designs (GSDs).5,14 During a
GSD, data are examined multiple times. At an interim
analysis, a test statistic comparing the intervention and
control arms for the outcome of interest—typically, a
clinical rather than a cost-effectiveness outcome—is cal-
culated. This test statistic is then compared with the pre-
specified stopping boundary (also known as a stopping
rule).
If the test statistic falls within the boundary, the trial
continues to the next analysis. This process is repeated at
each interim analysis using all accumulated evidence
until the test statistics cross the boundary or reach the
final analysis. Examples of stopping rules include those
proposed by Pocock15 and O’Brien-Fleming.16 Each rule
has different characteristics and impact on the design
and subsequent analyses.17 The Pocock rule requires a
larger maximum sample size if the trial does not stop
early; however, there is a lower hurdle for stopping the
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trial at early analyses compared with the O’Brien-Flem-
ing rule.
It is important to account for the adaptive nature of
the design during analysis to avoid introducing bias into
the trial results.14 Flight18 explored the impact that a
GSD can have on the health economic analysis following
a clinical trial and showed how it is important to adjust
for the adaptive design to maintain an accurate health
economic analysis.
In this article, we consider the appropriate adjustment
for the adaptive nature of the trial when extending VOIA
methods to guide the design of GSDs, highlighting the
additional considerations in the adaptive design setting.
Our approach allows researchers to determine a cost-
effective design by comparing different stopping rules
and number of interim analyses and to compare adaptive
with fixed-sample-size designs.
Methods
To conduct a VOIA for a fixed-sample-size design, Fen-
wick et al.12 proposed 7 steps in the ISPOR Value of
Information Emerging Good Practices Task Force gui-
dance. The following sections discuss each of these steps
in the context of employing an adaptive design, highlight-
ing how they differ from the fixed-sample-size design
case. Here, step 6 has been modified for adaptive designs.
This work was supported by a public advisory group
who ensured that the development of the methods was
relevant and appropriate from the public perspective.
More information on their role is provided by Flight.18
Steps 1 and 2: Conceptualize and Construct a Health
Economic Model and Parametrize with Evidence
As for fixed-sample-size designs, a health economic
model needs to be constructed for the population of
interest. This may be an existing model that has been
developed for the disease of interest or from previous
work such as a pilot study.
Steps 3 and 4: Generate the Probabilistic Sensitivity
Analysis Sample and Identify Uncertainty
A probabilistic sensitivity analysis (PSA) is generated
based on available prior evidence for the model para-
meters, denoted by u. Model parameters might include
transition probabilities, costs, and benefits for a health
state. We denote the PSA sample by
u
(1), . . . , u(NPSA)
 
ð1Þ
where NPSA is the number of PSA samples. For
each row of the PSA sample, the model is evaluated to
give a per-person net benefit for each intervention,
denoted by
NB(d, u(1)), . . . ,NB(d, u NPSAð Þ)
n o
ð2Þ
where d represents the interventions. There is no differ-
ence between the VOIA approach for a fixed-sample-size
and adaptive design at this stage.
Step 5: Establish whether Further Research is Worthwhile
The expected value of perfect information (EVPI) consid-
ers the scenario in which further research would eliminate
all decision uncertainty.19–21 Further research is poten-
tially worthwhile if the associated costs are less than the
EVPI.22 Using the same approach as for a fixed-sample-












It may be possible to resolve all the uncertainty about a
subset of the model parameters.10 This can be measured
using the expected value of partially perfect information
(EVPPI).20
Step 6: Estimate the Value of Specific Research
If the EVPI calculation suggests further research is
worthwhile, the value of different research designs can
be estimated by calculating the EVSI and expected net
benefit of sampling (ENBS). At this stage, additional
considerations are required for an adaptive design. We
break this step down into 6 stages:
1. Identify the trial designs for comparison.
2. Simulate the trial results and analysis data sets.
3. Calculate summary statistics adjusting the point esti-
mates and confidence intervals of primary and sec-
ondary endpoints to allow for the adaptive nature of
the trial design.
4. Calculate the EVSI.
5. Calculate the cost of sampling, accounting for any
additional and potential costs savings.
6. Compare the ENBS of the proposed trial designs.
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Stage 1: Identify the trial designs for comparison. The
first stage is to choose the trial designs for consideration,
which includes the sample size for the trial and the cri-
teria on which the trial might stop early (the stopping
rule). As discussed by Flight et al.,9 this is typically
informed by the clinical primary outcome, as cost-
effectiveness outcomes are rarely used in the design of an
adaptive trial. As with the fixed-sample-size design, and
using a frequentist approach to sample size calculation, this
will require an estimate of the clinically important difference
for the primary outcome, an estimate of the population var-
iance (for a normal outcome) and type I and type II errors
(typically chosen to be 0.05 and 0.1, respectively).23 These
choices are the same regardless of the adaptive nature of
the trial and are usually informed by prior information or
discussions with the clinical research team.
Additional considerations for an adaptive design—
specifically, a GSD here—include the choice of stopping
rule (based on the clinical primary outcome) and the
number of interim analyses. We consider GSDs with the
Pocock stopping rule and the O’Brien-Fleming stopping
rule with up to 5 equally spaced analyses of the data.
The sample size is informed by these choices.
Stage 2: Simulate the trial results and analysis data sets
accounting for the adaptive design. A trial result data set
representative of the population to be randomized into
the future trial is simulated for each row of the PSA sam-
ple. This is based on the likelihood function from existing
information such as a pilot study or observational study.
Rothery et al.10 suggested that data sets should be simu-
lated taking into account how the data from the trial would
be analyzed. Flight18 showed that the adaptive nature of a
trial can affect the subsequent health economic analysis.
Failing to adjust for this could result in a spurious estimate
of the EVSI, potentially wasting limited resources. They
also describe how bias-adjusted maximum likelihood esti-
mate methods for the adjustment of the point estimate and
the sample mean ordering approach to calculate adjusted
confidence intervals of primary and health economic out-
comes can be extended to adjust a within-trial and model-
based health economic analysis.24–26
In this article, the bias-adjusted methods are referred to
as the ‘‘adjusted analysis,’’ and the usual maximum likeli-
hood estimate is referred to as the ‘‘unadjusted analysis.’’
The data simulation is informed by the PSA para-
meter estimates to give a trial analysis data set in each
row of the PSA. The trial analysis for the design under
consideration is applied to each trial results data set. For
an adaptive design, this establishes whether the trial
would have stopped early at any of the interim analyses.
For example, the first group of simulated participants
form the analysis set at the first interim analysis. The pri-
mary outcome is calculated and compared with the pre-
specified stopping boundary. If the estimate crosses the
boundary, the trial stops and the trial analysis data set is
formed from the participants randomized into the trial
up to that point. If the boundary is not crossed, the trial
continues to the next interim analysis, until the point
estimate crosses the boundary or the final analysis is
reached. This is repeated for each row of the PSA sam-
ple. The accumulating cost-effectiveness data are not
used to inform whether the trial should stop early.
Stage 3: Calculate summary statistics. Summary statis-
tics for primary and secondary outcomes informing the
health economic model are estimated from the trial anal-
ysis data set in each row of the PSA sample. This will
include the primary and secondary clinical outcomes and
health economic outcomes, such as health care resource
use and health-related quality of life. These statistics are
denoted by
~T (y 1ð Þ), . . . , ~T (y(NPSA))
n o
, ð4Þ
for the adjusted analysis and by
T̂ (y 1ð Þ), . . . , T̂ (y(NPSA))
n o
, ð5Þ
for the unadjusted analysis.
Stage 4: Calculate the EVSI. The EVSI is the difference
between the expected net benefit given sample informa-
tion minus the expected net benefit given current infor-
mation. The health economic model has input
parameters (u) to estimate the net benefit of each inter-
vention (d = 1, . . . ,D) under consideration. This gives











for data Y to be collected.27 A population-level EVSI is
estimated by multiplying the individual-level EVSI by the
time horizon (T ) and the annual prevalence for the popu-
lation (Np) to give
28
popEVSI = EVSI 3T 3 Np: ð7Þ
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Methods for efficiently calculating the EVSI are summar-
ized by Health et al.29 and Kunst et al.30 We use the non-
parametric regression approach, as this does not require
the existence of conjugate distributions or parametric
assumptions.27
Stage 5: Calculate the cost of sampling accounting for
additional costs and cost savings. We need to understand
the costs associated with conducting the research, known
as the cost of sampling.31 The total cost of sampling is
composed of fixed, variable, analysis, and opportunity
costs and depends on the number of participants
recruited and number of analyses conducted. Fixed costs
are incurred regardless of the trial design and include site
recruitment and training, archiving costs, and dissemina-
tion. Variable costs include randomizing and following
up participants such as staff costs and database manage-
ment. The analysis costs include costs associated with
conducting an analysis of the endpoints used to inform
interim decision making (typically clinical endpoints).
For the fixed design, the cost of analysis is included in
the fixed costs. For the adaptive design, however, we sep-
arate this out, as multiple analyses may take place
depending on the design chosen.
The opportunity cost can be thought of as the finan-
cial cost of delaying a decision to obtain more informa-
tion.32 Willan and Kowgier33 suggested, for a 2-arm
trial, the opportunity cost is equal to the incremental net
benefit (INB) of the new intervention compared with the
control based on information available before the trial
begins.
The cost of sampling, for a 2-arm trial, is calculated
using




where TC is the total cost of sampling, Cf is the fixed
cost, Na is the expected number of analyses, Ca is the cost
of analysis, n is the expected sample size (ESS), Cv is the
variable cost per patient incurred by every participant in
the trial, nI is the expected number of participants in the
intervention arm, Cv, I is the variable cost per participant
incurred in the intervention arm only, nC is the expected
number of participants in the control arm, Cv,C is the
variable cost per participant incurred in the control arm
only, and Co is the opportunity cost per participant.
Additional information on how to calculate the cost of
sampling for an adaptive design is given in the supple-
mentary material.
Stage 6 and Step 7: Compare the ENBS of trial designs
and iterate with new evidence. The ENBS is the difference
between the population EVSI and the cost of sampling.
This can be calculated using the adjusted approach,
denoted by gENBS , or the unadjusted approach, denoted
by dENBS . The optimal design from a health economic
perspective has the highest ENBS. We use the ENBS to
guide the design of a clinical trial alongside discussions
with clinical teams, including the use of adaptive as well
as fixed-sample-size designs. As for the fixed-sample-size
design, this process should be repeated once new evidence
is available.
The steps for conducting a VOIA for a fixed-sample-
size design, proposed by Fenwick et al.,12 have been
extended for an adaptive design. These methods appro-
priately adjust the analysis for the adaptive nature of the
trial and capture the potential additional costs and cost
savings of these designs. The following sections outline a
hypothetical case study used to illustrate the approach
and summarize the results.
Hypothetical Case Study
We use a hypothetical case study, based on a real trial,
to illustrate how VOIA can be applied to an adaptive
design. The Cost-effectiveness of Aphasia Computer
Treatment Compared to Usual Stimulation (CACTUS)
pilot clinical trial aimed to assess the feasibility of con-
ducting a large-scale clinical trial into the effectiveness of
self-managed computer treatment for people with long-
standing aphasia post stroke.12 Participants were rando-
mized to either receive a computer-based intervention
(CSLT) designed to improve word-finding ability
through language exercises or a usual care control (UC).
A model-based cost-utility analysis of pilot data pro-
vided an early analysis of the likely cost-effectiveness of
CSLT, and full details are reported by Latimer et al.34
We considered alternative designs for a full-scale clini-
cal trial following the CACTUS pilot comparing CSLT
and UC. Using R, we adapted the original model and
analysis methods reported by Latimer et al,34 and the
proposed designs did not attempt to replicate the Big
CACTUS clinical trial or health economic analysis that
followed the CACTUS pilot trial.35 Full details on the
economic model used in this analysis are provided by
Flight.18
Trial design and data characteristics. We compared a
fixed-sample-size design, Pocock (POC)15 and O’Brien-
Fleming (OBF)16 stopping rules with maximums of 2
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and 5 analyses. Each design was applied in R (version
3.4.3) using the RCTdesign package (http://www.rctde-
sign.org/Welcome.html). For each design, the type I and
type II error rates were 0.05 and 0.1, respectively. The
clinically important difference was the improvement in
proportion of words named correctly between the inter-
vention and control arm (treated as a continuous vari-
able). That and its associated standard deviation were
calculated using the pilot trial data.
To explore the impact of different trial designs and
data characteristics on the choice of optimal design, the
correlation between primary and health economic out-
comes and the intervention costs were varied. We assumed
there was a negative correlation between the primary out-
come and costs and a positive correlation between the pri-
mary outcome and utilities. Absolute correlations of 0.0,
0.4, and 0.8 were explored, covering a range of no,
medium, and high correlation. The cost of CSLT was var-
ied over 15 values, and the INB from the pilot trial and
the subsequent EVSI and ENBS was recalculated.
Data-generating mechanism. To generate the PSA sam-
ple, we bootstrapped the CACTUS pilot data 5000
times. We simulated a trial result data set for each of the
PSA rows using copulas. This allowed the marginal dis-
tributions of the primary and the health economic out-
comes (resource costs and utility) to be nonnormal and
correlated. Full details are provided in the supplementary
material. We used a willingness-to-pay threshold of
£20,000 per quality-adjusted life-year as per National
Institute for Health and Care Excellence guidance with a
discount rate of 3.5% applied to costs and benefits.36 The
time horizon and prevalent population were taken from
the Latimer et al.34 pilot health economic analysis, giving
an average of 27,616 patients expected to eligible for and
compliant with CSLT per year over a 10-y period.
Trial results estimates. We calculated adjusted and
unadjusted estimates of the health economic model para-
meters using the bias-adjusted maximum likelihood esti-
mates described by Flight,17 compared adjusted and
unadjusted point estimates of the primary clinical out-
come, and reported the width of the 95% confidence
interval. We then calculated and compared the ENBS
for each of the scenarios to determine the optimal trial
design from a health economic perspective.
Results
We summarize how the results of such analyses could be
presented when exploring the optimal trial design,
including both fixed-sample-size and adaptive designs, by
first considering the impact of each design on the maxi-
mum and ESS for the trial, the difference in the cost of
sampling, and how the EVSI and ENBS for the designs
might be compared visually and summarizing the poten-
tial impact of the unadjusted versus the adjusted
approaches. FIX denotes the fixed-sample-size design,
and OBF2 and OBF5 and POC2 and POC5 denote the
O’Brien-Fleming and Pocock designs with 2 and 5 analy-
ses, respectively. The specific results from applying the
new VOIA methods to the hypothetical case study are
context dependent and not generalizable to all VOIA cal-
culations using this approach.
Maximum and ESS and Proportion of Trials Stopping at
Each Analysis
Table 1 summarizes the ESS, number of analyses, and
distribution of the sample size for each design over the
interim and final analyses with zero correlation between
the primary and health economic outcomes. OBF5 has
the highest expected number of analyses (4.55 analyses)
and POC2 the fewest (1.79 analyses). Both POC designs
have a high maximum sample size because of the large
penalty for early examinations of the data. The ESS for
these designs is high, as a large proportion of trials reach
the final analysis where the sample size is larger than the
fixed-sample-size design. A small number of trials
(0.02%) stopped at the first interim analysis of OBF5,
based on the accumulating evidence for the primary out-
come, where the sample size was 60. In contrast, almost
5% of trials stopped at the first analysis of POC5, where
the sample size was 72.
Calculating the Cost of Sampling for the Case Study
Financial information from the Big CACTUS grant
application (not the actual costs incurred) was used to
inform the cost of sampling for the hypothetical CAC-
TUS case study. These detailed costs are routinely out-
lined in the planning of clinical trials and are a useful
source for any trial team considering this approach. The
components of the cost of sampling for the hypothetical
case study are given in the supplementary material.
The cost of sampling for each design is given in Table
1. The cost of sampling for FIX is £2,127,530, the highest
cost of sampling of the 5 designs. POC2, OBF2, and
OBF5 have similar costs of sampling because of their
similar ESS. POC5 has the highest costs of sampling;
however, this is only £140,000 greater than the cheapest
design (OBF5), which is relatively small given each design
has a cost of sampling greater than £2,000,000. Even
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when a trial can stop at the first analysis, large costs are
incurred, especially when the first analysis is conducted
halfway through the trial. The trials stopping at the first
analysis of 5 have the smallest cost of sampling, as they
have one-fifth of the maximum number of participants.
This is slightly smaller for OBF as the first analysis is
conducted on the fewest number of participants.
EVSI and ENBS
Table 2 gives the unadjusted EVSI and ENBS for FIX,
as there are no early examinations of the data, there is no
need to adjust the final analysis. The adjusted EVSI and
ENBS are presented for the 4 adaptive designs to reflect
the adjustments required.
OBF2 has the highest EVSI and ENBS. From a cost-
effectiveness perspective, this is the optimal trial design.
This design gives a high EVSI but incurs a smaller cost of
sampling compared with FIX and POC (see Table 1). The
saving in costs of the additional, earlier analyses of OBF5
do not outweigh the reduction in EVSI as a result of the
smaller ESS. Likewise, both POC designs do not perform
well, as only a small number of trials stop early, and so the
trial has a large cost of sampling with no gain in EVSI.
Table 2 Results for 5 Proposed Trial Designs under 3 Different Scenarios for the Extent of Correlation between Primary and
Health Economic Outcomes, with Correlation 0.0, 0.4, and 0.8. Based on 5000 Probabilistic Sensitivity Analysis Samplesa
Design FIX OBF 2 OBF 5 POC 2 POC 5
Correlation = 0.0
EVSI per patient (SE) 26.62 (5.17) 27.27 (5.60) 26.20 (5.41) 25.83 (5.49) 25.13 (5.41)
Population EVSI (million) 7.35 7.53 7.23 7.13 6.94
ENBS (£ million) 5.22 5.46 5.20 5.04 4.76
Correlation = 0.4
EVSI per patient (SE) 39.91 (6.12) 40.56 (6.32) 38.84 (6.05) 37.99 (5.83) 40.91 (6.43)
Population EVSI (million) 11.02 11.20 10.73 10.49 11.30
ENBS (£ million) 8.89 9.13 8.69 8.39 9.12
Correlation = 0.8
EVSI per patient (SE) 36.25 (5.83) 40.13 (6.08) 37.95 (6.12) 37.68 (5.92) 38.56 (5.99)
Population EVSI (million) 10.01 11.08 10.48 10.41 10.65
ENBS (£ million) 7.88 9.01 8.44 8.31 8.47
ENBS, expected net benefit of sampling; EVSI, expected value of sample information; OBF O’Brien-Fleming stopping rule; POC, Pocock
stopping rule.
aUnadjusted values are presented for FIX and adjusted values for the adaptive designs. Values in bold show the most efficient design.
Table 1 Expected Number of Analyses, Expected Sample Size, Proportion of Trials Stopping at Each Analysis, and Expected
Cost of Sampling for 5000 Probabilistic Sensitivity Analysis Samples, Assuming Zero Correlation between the Primary and
Health Economic Outcomes
Design Analysis FIX OBF 2 OBF 5 POC 2 POC 5
Expected number of analyses 1.00 1.91 4.55 1.79 4.28
Maximum sample size 292 294 300 320 352
Expected sample size 292.00 280.66 273.05 285.73 301.52
Proportion of simulated trials stopping
at each analysis (expected No. of
participants at each analysis)
1 1.00 (292) 0.09 (148) 0.00 (60) 0.21 (160) 0.05 (72)
2 — 0.91 (294) 0.03 (120) 0.79 (320) 0.09 (142)
3 — — 0.11 (180) — 0.09 (212)
4 — — 0.13 (240) — 0.07 (282)
5 — — 0.73 (300) — 0.70 (352)
Expected cost sampling (£million) 2.13 2.07 2.04 2.10 2.18
Expected cost of sampling for a trial stopping
at each analysis (£ million)
1 2.13 1.42 0.98 1.48 1.04
2 — 2.14 1.28 2.27 1.39
3 — — 1.57 — 1.73
4 — — 1.87 — 2.08
5 — — 2.17 — 2.42
OBF, O’Brien-Fleming stopping rule; POC, Pocock stopping rule.
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The 95% confidence intervals for the estimated EVSI
are wide and overlapping for all scenarios. Increasing the
number of PSA samples may reduce the variance; how-
ever, this will need to be balanced against the increased
computation time. As this estimate is used to calculate
the ENBS, the choice of design for the trial is uncertain if
considering the EVSI and ENBS for 5000 PSA samples.
Varying Intervention Costs in the Case Study
Figure 1 summarizes the ENBS for the 5 proposed
designs for increasing intervention costs. This provides a
useful way to visualize and compare the competing trial
designs to identify the optimal option under increasing
intervention costs, identifying scenarios in which differ-
ent designs may be optimal. In the hypothetical case
study, the OBF2 design performs best for all correlations
when the intervention costs are low, as they have a higher
EVSI and low cost of sampling. The POC5 design also
performs well for lower intervention costs, especially
when correlations are equal to zero and 0.8, as it has a
high EVSI that outweighs its high cost of sampling.
However, once the intervention costs are higher than
approximately £8000 the designs with the smaller cost of
sampling are preferable because of the small EVSI gained
from all designs. Hence, the designs with 5 analyses per-
form better.
The ENBS increases as the intervention cost increases,
as there is greater uncertainty in the cost-effectiveness
decision. Once the intervention costs reach £3846, this
uncertainty decreases, as it becomes clearer that the
CSLT is unlikely to be cost-effective. POC5 performs
well when there is highest uncertainty, as this has the
highest ESS and thus the opportunity to learn more
information from more participants.
Comparison of Adjusted and Unadjusted EVSI
Table 3 summarizes the adjusted and unadjusted esti-
mates of the EVSI, ENBS, health economic model para-
meters, and the primary outcome from the PSA samples.
There is no difference between estimates for the baseline
utility in the control arm, as this is not affected by the
design of the trial and is thus set to be equal.
Figure 1 Case study sensitivity to the intervention cost assumption. Expected net benefit of sampling (ENBS) for 5 designs (5000
PSA samples). The adjusted ENBS is presented for the adaptive designs and the unadjusted ENBS for the fixed-sample-size
design.
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Table 3 Adjusted and Unadjusted Estimates of the EVSI, ENBS, and their Percentage Differences for Health Economic Model Parameters and the Clinical
Primary Outcome
Design FIX OBF 2 OBF 5 POC 2 POC 5 FIX OBF 2 OBF 5 POC 2 POC 5 FIX OBF2 OBF 5 POC 2 POC 5
Correlation 0.0 0.4 0.8
EVSI Adjusted — 27.3 26.2 25.8 25.1 — 40.6 38.8 38.0 40.9 — 40.1 37.9 37.7 38.6
Unadjusted 26.6 25.8 24.4 24.1 23.8 39.9 37.2 35.2 36.0 36.9 36.2 35.4 34.9 34.5 35.9
% Difference — 5.6 7.3 6.8 5.4 — 8.7 9.8 5.4 10.3 — 12.5 8.4 8.8 7.2
ENBS Adjusted — 5.5 5.2 5.0 4.8 — 9.1 8.7 8.4 9.1 — 9.0 8.4 8.3 8.5
Unadjusted 5.2 5.0 4.7 4.6 4.4 8.9 8.2 7.7 7.8 8.0 7.9 7.7 7.6 7.4 7.7
% Difference — 7.8 10.3 9.8 8.0 — 10.8 12.2 6.9 12.9 — 15.6 10.5 11.2 9.1
Resource cost intervention arm Adjusted — 201.4 201.4 201.6 201.8 — 201.9 201.9 202.1 202.6 — 202.3 202.5 202.4 202.8
Unadjusted 201.5 201.4 201.4 201.6 201.8 201.6 201.4 201.4 201.4 201.1 202.2 201.9 201.9 201.8 201.6
% Difference — 0.0 0.0 0.0 0.0 — 0.2 0.2 0.3 0.7 — 0.2 0.3 0.3 0.6
Resource cost control arm Adjusted — 269.8 269.7 269.7 269.6 — 269.6 269.5 269.5 269.1 — 269.4 269.3 269.3 268.9
Unadjusted 269.8 269.8 269.7 269.6 269.5 269.9 270.1 270.2 270.1 270.5 269.8 269.8 269.9 269.8 270.2
% Difference — 0.0 0.0 0.0 0.0 — –0.2 –0.3 –0.2 –0.5 — –0.2 –0.2 –0.2 –0.5
Utility improvement Adjusted — 0.0 0.0 0.0 0.0 — 0.3 0.3 0.3 0.3 — 0.2 0.2 0.2 0.2
Unadjusted 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2
% Difference — –0.3 –0.5 –0.4 –1.0 — –1.0 –1.5 –1.4 –3.1 — –1.0 –1.5 –1.4 –3.1
Probability of a good response Adjusted — 0.4 0.4 0.4 0.4 — 0.4 0.4 0.4 0.4 — 0.4 0.4 0.4 0.4
Unadjusted 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
% Difference — –2.1 –2.4 –2.3 –3.4 — –2.1 –2.4 –2.3 –3.4 — –2.0 –2.3 –2.3 –3.4
Probability of relapse Adjusted — 0.0 0.0 0.0 0.0 — 0.0 0.0 0.0 0.0 — 0.0 0.0 0.0 0.0
Unadjusted 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
% Difference — –11.2 –12.6 –12.1 –17.5 — –14.3 –16.0 –15.4 –21.3 — –13.6 –15.0 –15.0 –19.7
Treatment effect Adjusted — 0.1 0.1 0.1 0.1 — 0.1 0.1 0.1 0.1 — 0.1 0.1 0.1 0.1
Unadjusted 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
% Difference — –5.4 –7.9 –7.2 –16.1 — –5.4 –7.9 –7.2 –16.0 — –5.4 –7.9 –7.2 –16.0
Width treatment effect CI Adjusted — 0.2 0.2 0.2 0.2 — 0.2 0.2 0.2 0.2 — 0.2 0.2 0.2 0.2
Unadjusted 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
% Difference — 34.1 33.9 34.3 36.5 — 34.1 34.0 34.4 36.5 — 34.1 34.1 34.3 36.5
ENBS, expected net benefit of sampling; EVSI, expected value of sample information; OBF O’Brien-Fleming stopping rule; POC, Pocock stopping rule.
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The difference between the adjusted and unadjusted
estimates of the primary outcome is greatest for the adap-
tive designs with 5 analyses compared with 2 analyses
and highest for POC compared with OBF. The point esti-
mates are likely to be based on less data, as the interim
sample size for early analyses out of 5 is small and the
POC stopping boundary is more likely to be crossed at
an early interim analysis by design. The adjusted confi-
dence intervals are wider, reflecting the additional uncer-
tainty introduced by the adaptive design.
The differences between the model parameters are
small and close to zero for the cost parameters and the
utility improvement. The percentage differences are
higher for the probability of good response and prob-
ability of relapse, reaching 3.42% and 21.29%, respec-
tively. The primary outcome is used to calculate these
model parameters and is biased even when there is no
correlation between primary and health economic out-
comes. The differences for all parameters are greatest for
POC5 within each correlation and greatest when the cor-
relation is equal to 0.4.
Overall, the impact of the adjustments for the hypothe-
tical case study is small, with the optimal design changing
only when the correlation is 0.4. The adjusted EVSI
estimates for the adaptive designs are larger than the
unadjusted estimates. The increased EVSI could suggest
greater uncertainty as a consequence of the analysis meth-
ods used to estimate the adjustments or could reflect the
fact that unadjusted approaches underestimate the uncer-
tainty introduced by the adaptive design.
The EVSI values change when there is a change in the
decision uncertainty.12 If the bias adjustments have little
impact on the decision uncertainty, there will be only
small differences between the adjusted and unadjusted
EVSI estimates, even if there are large differences
between the adjusted and unadjusted model parameters
estimates. This is illustrated using 2 hypothetical scenar-
ios in the supplementary material.
Case Study Summary
In the hypothetical case study, we found small differ-
ences in the cost of sampling between designs driven by
small differences in the ESS. The ENBS was positive and
similar for each of the designs, suggesting they were all
cost-effective. The effect of the bias adjustment was small
and had limited impact on choosing the optimal design.
The O’Brien-Fleming stopping rule with 2 analyses had
the highest EVSI and ENBS, suggesting this was the
most cost-effective design. As the intervention costs were
increased and ENBS was recalculated, the potential sav-
ings in ESS offered by the adaptive designs gave them a
higher ENBS. The O’Brien-Fleming stopping rule with 5
analyses was preferred when variable costs were high, as
they offered early interim analyses with a small number
of participants and hence a lower ESS and cost of sam-
pling when there was little to be gained in terms of EVSI.
The financial benefits of stopping a trial early are likely
to be small when the fixed costs are high relative to the
variable costs and likewise when the variable costs asso-
ciated with assessing the trial outcomes in all patients
may be high.
Discussion
We have adapted existing methods of EVSI to guide the
design of fixed-sample-size designs to the case of consid-
ering adaptive designs. These methods appropriately
adjust for the adaptive nature of the design and have
been operationalized in the context of a hypothetical case
study.
How This Fits with Existing Literature
We have considered adaptive designs with clinical effec-
tiveness stopping rules based on recommendations by
Flight et al.11 and suggestions from the public advisory
group supporting this research. However, application of
VOIA methods could be extended and applied at the
interim analysis of an adaptive design to allow research
teams to assess the cost-effectiveness of continuing and
to inform the design of the rest of the trial. A simple
approach would be to update the EVSI calculation with
the available data at the interim; however, this does not
take account of all possible future interim analyses.
Using health economic outcomes during an adaptive
trial has been discussed in the literature33,37–39; however,
care is needed to ensure the preferences of stakeholders
are met.11
The EcoNomics of Adaptive Clinical Trials (ENACT)40
collaboration has explored how the value-based sequential
approach of Chick et al.39 and Alban et al.41 can be
applied in the context of publicly funded research in the
United Kingdom. Using 2 retrospective case studies, they
considered the methodology’s strengths, such as consider-
ing the ultimate technology adoption decision in the
design and analysis of a trial, and challenges, including
the application of the methods within current funding
structures.42,43
Implications for Practice and Research
We recommend researchers adjust analyses for the adap-
tive nature of the designs to avoid introducing bias,
10 Medical Decision Making 00(0)
reflecting current reporting and regulatory guidance for
adaptive designs.44,45 As discussed by Flight,17 adjusted
model parameters cannot always be directly estimated
from the trial data, and so alternative methods are
required. As such, the difference between adjusted and
unadjusted estimates may be a consequence of the differ-
ent analysis methods as well as biases introduced by
the design. We reported the adjusted estimates for the
adaptive designs and unadjusted estimates for the fixed-
sample-size designs, as we felt that this best reflected the
analysis approach that would be undertaken in practice
and reflected current guidance.10
The VOIA approach outlined offers a formal way to
quantify and compare the value of fixed-sample-size and
adaptive designs. This will enable researchers to provide
a quantified justification for their choice of adaptive
design as per the recent guidance from the Food and
Drug Administration in the United States.45 We antici-
pate these methods will also be used by research teams
to inform discussions on the best choice of trial design.
We have compared the ESS, EVSI, and ENBS to
identify the optimal design. Other factors may include
the potential maximum sample size. As discussed, the
Pocock stopping rule requires a larger sample size if the
trial does not stop early compared with the O’Brien-
Fleming rule. Funders, for example, will need to consider
the financial and practical implications should the trial
continue to the maximum sample size.
Following the approach of Willan and Kowgier,33 we
have assumed the opportunity cost is equal to the a priori
INB. However, this will be true only if the new interven-
tion cannot be implemented in practice before the trial
ends. The opportunity cost may be zero if the interven-
tion is potentially cost-effective and can be used in prac-
tice while research is ongoing.46 Research teams should
select the appropriate opportunity cost for their setting.
Using this approach may require a large investment
of work before the trial is funded. In the CACTUS case
study, pilot data and a health economic model were
available, reducing the time burden of the VOIA. Appli-
cation of this approach may be limited to contexts in
which an economic model is available or a model can be
developed quickly alongside the design of the trial. As
highlighted by Flight et al.,11 for these methods to be
used to their full potential, funding bodies need to con-
sider alternative ways to fund this work.
As with other EVSI methods, the computation time is
high.27,47 For 5000 PSA samples, it took approximately 5
and 7 h to run the designs with 2 and 5 analyses, respec-
tively. A full range of trial designs should be compared
with a high number of PSA samples.10 However, this
may not be viable given the time constraints associated
with designing clinical trials for a grant application.
Alternative methods for the calculation of EVSI47–50
could decrease the computation time.
We have focused on the commonly used GSD; how-
ever, this approach could be considered for other adap-
tive designs. For example, Ward et al.51 used EVSI to
compare the optimal design of a 3-arm trial with and
without an interim futility analysis.
Strengths and Limitations
To the best of our knowledge, this is the first adaptation
of EVSI to guide the design of a GSD in which interim
adaptations are focused on clinical effectiveness. These
methods reflect the views of key stakeholders in health
technology assessment on the use of health economics in
adaptive design11 and build on existing guidance and
methods in VOIA.10,12,27 These methods have the poten-
tial to affect the design of adaptive trials that are increas-
ingly used in practice.5
We have used a hypothetical case study to illustrate
how the methods can be applied in practice. The results
are context specific; for example, there were small differ-
ences between the ENBS for the designs considered, and
the bias adjustments had a limited impact. We cannot
draw generalizable conclusions about the performance of
adaptive and fixed-sample-size designs. However, the
adapted VOIA methods and the presentation of the
results can be applied to different contexts.
Conclusion
Health economics is rarely used in the design and analy-
sis of adaptive clinical trials. We discuss how existing
VOIA methods can be adapted to guide the design of a
GSD based on the number of analyses and clinical effec-
tiveness stopping rule. This can guide and justify the
choice of characteristics and prevent limited research
budgets being wasted. We recommend that adjusted
analyses are presented to control for the potential impact
of the adaptive designs to maintain the accuracy of the
calculations.
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